Protagonist Therapeutics, Inc. PTGX 深 滬
交易中 07-18 12:06:40 美东时间
56.55
+0.110
+0.19%
華盛通- 最 高56.89
- 今 開56.83
- 成交量 9.61万股
- 最 低 56.00
- 昨 收 56.44
- 總市值 35.05亿
- 52周最高 60.60
- 市盈率 靜 13.37
- 換手率 0.16%
- 52周最低 32.50
- 委 比 -87.50%
- 總股本 6198.20万
- 歷史最高 60.60
- 量 比 0.38
- 振 幅 1.58%
- 歷史最低 4.47
- 每 手 1
- 風險率 5.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：PTGX MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-28 07:00
Protagonist Therapeutics to Reveal Oral Obesity Drug Development Candidate and Study Results in Upcoming Call
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and
06-26 19:09
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Citigroup Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $72
Citigroup analyst Geoff Meacham initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $72.
06-17 19:44
9 Analysts Assess Protagonist Therapeutics: What You Need To Know
In the latest quarter, 9 analysts provided ratings for Protagonist Therapeutics...
06-03 20:01
Reported Sunday, Protagonist And Takeda Present 32-Week VERIFY Data: Rusfertide Significantly Reduces Phlebotomy, Improves Symptoms In Polycythemia Vera
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care,
06-02 15:42
强生亮出底牌
（转自：药剂Talks） 强生频繁亮出新王牌，按下了自免王座争夺战的加速键。 4月30日，强生的FcRn阻断剂Nipocalimab（尼卡利单抗）获FDA批准...
05-22 19:06
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 price target.
05-19 18:34
Protagonist Announces Icotrokinra Phase 3 Data On PN-881 Presented At Society For Investigative Dermatology Annual Meeting
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate a standout
05-09 20:09
